Pfizer has secured a $10 billion acquisition of obesity drug developer Metsera, outbidding rival Novo Nordisk in a heated ...

Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.

Pfizer prevails 10B bidding for Metsera, securing a deal to expand its obesity drug portfolio with innovative weight-loss treatments.

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...

Cogent Biosciences said its experimental drug, called bezuclastinib, lowered the risk of tumor progression or death by 50% ...

Pfizer's agreement to buy Metsera just adds to the 83 healthcare deals counted by Goldman Sachs that were above $100 million ...

Pfizer Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

“No need for a reunion show: This seasons Real Housewives of Biopharma comes to a close with Pfizer’s winning bid for Metsera ...

Indiana's harvest nears completion, Pfizer acquires weight-loss drug company, YouTube TV issues refunds, and Starbucks ...

Metsera shares fell significantly as the firm accepted a $10 billion offer from Pfizer, ending its bidding war with Novo Nordisk. Despite the dip, Metsera shares have surged since Pfizer's initial ...

Novo Nordisk stock rose 2.6% after withdrawing from a $10 billion bidding war for Metsera that investors viewed as too ...

Metsera shares fell sharply in premarket trading Monday after the weight-loss drug startup struck a revised deal to be acquired by Pfizer, prompting Danish drugmaker Novo Nordisk to drop out of a ...